Keyword: Congress

Two Republican lawmakers advised drugmakers to not participate in a drug pricing probe in a House committee.

Merck CEO Kenneth Frazier remains unflustered by his company's challenges, thanks to advice his father gave him when he was a teenager in Philadelphia.

The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.

If Boehringer Ingelheim is already stockpiling for its rollout, it's also stepping on Humira's patents, AbbVie argues.

A new bill to legalize insulin imports comes amid a congressional probe of pricing directed at insulin makers Sanofi, Novo Nordisk and Eli Lilly.

Think the entire pharma industry has moved past the old strategy of buying drug rights, jacking up prices and reaping the rewards? Think again.

Catalyst is unfazed by a letter from Sen. Bernie Sanders demanding that it justify the cost of its rare-disease drug Firdapse, confirmed at $300K after discounts.

UnitedHealthcare is making demands about pharma's new strategy to lower prices, an analyst wrote.

Reps. Frank Pallone Jr. and Diana DeGette sent letters to executives of insulin makers requesting answers about pricing.

Between President Trump on Twitter and critics in Congress, pharma and its pricing faced daily fire last year. But the industry's top lobbyists shot back.